Company overview. Canda HEC 1 LLC (styled CANDA HEC-1, LLC in filings) is a Texas domestic limited liability company formed on November 25, 2014, with its principal place of business at 1404 South New Road, Waco, Texas. It is not an operating company: Texas records list Canda Pharma LLC (an inactive affiliate, formed 2013) as registered agent and Burford Capital Investment Management LLC as manager, and its Rule 7.1 disclosure identifies corporate parent Burford Capital LLC. Burford Capital (NYSE/LSE: BUR) is the world's largest litigation-finance firm, which funds third parties' legal claims in exchange for a share of recoveries. No revenue, headcount, or product figures for Canda itself are publicly reported; it functions as a special-purpose litigation vehicle.
Products / services / operations. Canda HEC 1 LLC has no products, services, facilities, or employees of its own. Court filings describe it as having "contractual relationships" with HEC Pharm Co., Ltd. and Rising Pharma Holdings, Inc. relating to HEC's generic drug product — consistent with a litigation-funding and profit-sharing arrangement rather than a commercial business. It is best characterized as a funding/affiliate shell tied to the HEC Pharm group's U.S. patent disputes, not an NPE asserting its own patent portfolio.
Patent-litigation posture. Canda is a defendant, not a plaintiff, in the single tracked case: Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. et al. (filed Jan. 28, 2020, U.S. District Court for the District of Delaware, No. 1:20-cv-00133). It was named alongside HEC Pharm Co., Ltd. (China), HEC Pharm USA Inc., Sunshine Lake Pharma Co., Ltd., and Rising Pharma Holdings. This is a Hatch-Waxman ANDA dispute in which Novartis, brand owner of the multiple-sclerosis drug Gilenya® (fingolimod), alleged that HEC's generic label induces infringement of U.S. Patent No. 10,543,179 ("Dosage Regimen of an S1P Receptor Modulator," covering a VZV-testing/vaccination dosing regimen). Canda's role is that of a litigation-finance counterparty aligned with the generic defendants, and in related Delaware actions HEC and Canda have jointly pursued monetary relief against Novartis for wrongful injunction.
Notable context. The Delaware litigation is part of a multi-year series of cases between Novartis and HEC over generic fingolimod, including earlier '405-patent litigation that reached the Federal Circuit and a Supreme Court certiorari petition (denied). Canda's involvement — and its Burford Capital parentage — makes it a visible example of third-party litigation funding in pharmaceutical ANDA patent fights, with Burford standing to share in any recovery HEC obtains from Novartis.